Anavex presents data on neuroprotective evidence for ANAVEX 2-73, lead compound for Alzheimer's disease
Sources News Release
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 26/07/2011
Year Published: 2011
Resource Type: Article
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimers Association International Conference (AAIC) held in Paris, entitled Preclinical development of new tetrahydrofur
Abstract: Hoboken, NJ July 26, 2011 -- Anavex Life Sciences Corp. (Anavex) (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimers Association International Conference (AAIC) held in Paris, entitled Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimers disease.
Neuroprotective, anti-amnesic, anti-depressive and anti-convulsive effects have previously been described with a ne...
To read the full release go to http://www.sources.com/Releases/NR1383.htm
© 2019. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.